GSK’s asthma biologic hits quality of life goal

Pharma Times ----- GlaxoSmithKline has presented new data showing that its asthma drug Nucala “significantly improves” quality of life and lung function in patients with a severe, eosinophilic form of the condition. The Phase IIIb MUSCA study successfully met all its primary and secondary endpoints, showing that when the first-in-class biologic was added to standard of care, patients experienced clinically and statistically significant improvements in their health-related quality of life and lung function compared to those treated with placebo and standard of care. To learn more click on the picture below to read the article.